Omada Health (NASDAQ:OMDA) Stock: Insider Sean Duffy Sells 12,944 Shares

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 12,944 shares of the business’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $19.22, for a total transaction of $248,783.68. Following the sale, the chief executive officer directly owned 382,594 shares in the company, valued at approximately $7,353,456.68. This trade represents a 3.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Omada Health Stock Performance

Omada Health stock opened at $15.09 on Friday. The firm’s 50 day moving average price is $20.14 and its two-hundred day moving average price is $17.74. The firm has a market cap of $923.81 million, a PE ratio of 71.86 and a beta of 2.13. Omada Health, Inc. has a twelve month low of $10.28 and a twelve month high of $25.45.

Omada Health (NASDAQ:OMDA) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.02 by $0.08. Omada Health had a net margin of 4.21% and a return on equity of 5.91%. The business had revenue of $91.31 million for the quarter. Equities analysts anticipate that Omada Health, Inc. will post 0.09 EPS for the current fiscal year.

Trending Headlines about Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Omada reported Q3 revenue of $91 million, up 34% year over year, and total members grew 36% to a record 1.1 million. Net income was $7 million versus a year-ago loss, while adjusted EBITDA increased to $12 million. The company also raised its full-year 2026 financial outlook. Omada Health Reports Third Quarter 2026 Results
• Positive Sentiment: Quarterly revenue exceeded FactSet’s estimate, and reported earnings also topped consensus estimates, providing evidence of stronger-than-expected operating performance. Earnings Flash: Q3 Revenue
• Neutral Sentiment: Unusual options activity was reported after Omada’s earnings, signaling heightened trading interest but not indicating a clear direction for the stock. Unusual Options Volume Report
• Negative Sentiment: Several analysts took a more cautious stance: Wells Fargo cut its price target to $19 and maintained an “equal weight” rating, while Zacks Research downgraded OMDA from “strong buy” to “hold.” Wells Fargo analyst actions Zacks Research analyst action
• Negative Sentiment: Barclays also lowered its target from $24 to $22, although it retained an “overweight” rating. Barclays analyst action

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Robert W. Baird upped their target price on Omada Health from $15.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 12th. Barclays reduced their price target on Omada Health from $24.00 to $22.00 and set an “overweight” rating for the company in a report on Friday. Citizens Jmp boosted their price target on Omada Health from $27.00 to $32.00 and gave the company a “market outperform” rating in a research note on Friday, August 14th. Citigroup restated an “outperform” rating on shares of Omada Health in a report on Friday, August 14th. Finally, BTIG Research reaffirmed a “buy” rating and set a $35.00 price objective on shares of Omada Health in a research report on Friday, September 11th. Eleven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $26.33.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Walleye Capital LLC acquired a new stake in shares of Omada Health during the 2nd quarter valued at about $11,648,000. GSA Capital Partners LLP acquired a new position in Omada Health in the second quarter worth about $1,289,000. Quantinno Capital Management LP raised its position in Omada Health by 464.1% in the first quarter. Quantinno Capital Management LP now owns 58,723 shares of the company’s stock worth $738,000 after purchasing an additional 48,313 shares in the last quarter. AlpInvest Partners B.V. bought a new position in Omada Health during the second quarter worth about $1,182,000. Finally, Corient Private Wealth LP bought a new position in Omada Health during the second quarter worth about $3,108,000.

Omada Health Company Profile

Omada Health, Inc (NASDAQ: OMDA) is a digital health company that provides virtual care programs for people managing chronic conditions. Its platform combines personalized health coaching, clinical support, behavioral-change tools and connected devices to help members monitor and improve their health.

The company’s offerings focus primarily on cardiometabolic conditions, including diabetes, prediabetes, hypertension and obesity, as well as musculoskeletal conditions. Depending on the program, members may receive access to digital lessons, health tracking, remote monitoring, care teams and clinical guidance through Omada’s technology platform.

Omada Health was founded in 2011 and serves employers, health plans and other healthcare organizations in the United States.